Press release
direct/ 4AZA Bioscience N.V. (BE): 4AZA BIOSCIENCE ANNOUNCES RESEARCH COLLABORATION WITH GILEAD
Companies to Pursue Early-Stage Compounds for the Treatment of Hepatitis CLeuven, Belgium, November 30, 2005 -- 4AZA Bioscience NV today announced that the company has entered into a licensing agreement with Gilead Sciences of Foster City, California to research and develop compounds for the potential treatment of hepatitis C virus (HCV) infection, a therapeutic area representing a significant unmet medical need. These compounds, discovered by 4AZA, will be screened and evaluated preclinically by Gilead.
Under the terms of the agreement, 4AZA will grant to Gilead an exclusive, worldwide license for the research, development and commercialization of certain novel compounds for the potential prevention and treatment of HCV. Gilead will pay an upfront licensing fee and make an equity investment in 4AZA. 4AZA will also receive milestone payments based on the achievement of certain development and regulatory goals, should one or more compounds be advanced into clinical development, and a royalty of net sales of any marketed product resulting from the collaboration. Additionally, Gilead will provide funding to 4AZA to support research staff to synthesize new compounds that may have potential activity against HCV. 4AZA will retain rights to develop and commercialize certain compounds evaluated under the companies´ agreement for other indications.
"This agreement with Gilead Sciences, a world leader in the development of anti-viral drugs, is a clear recognition of the value of the 4AZA proprietary library of heterocyclic compounds," said Mark De Boer, PhD, President and CEO of 4AZA.
"The compounds discovered by 4AZA represent a new class of compounds with the potential of inhibiting HCV replication by a novel mechanism," said William Lee, PhD, Gilead´s Senior Vice President Research.
About Hepatitis C Virus
Hepatitis C is a viral liver disease, caused by infection with the hepatitis C virus. Globally, more than 170 million people have chronic hepatitis C. Hepatitis C is one of the primary causes of liver failure and transplantation in the United States. Currently, there is no vaccine that can protect against hepatitis C infection.
About 4AZA Bioscience NV
4 AZA Bioscience NV is a drug discovery and development company focusing on immunomodulatory diseases including rheumatoid arthritis and immunosuppression for solid organ transplantation patients. 4AZA exploits the biochemistry of pteridine and deazapteridine molecules to identify novel immunomodulatory compounds. 4AZA has a competitive advantage in this unexplored area of chemical space which is likely to give rise to identification of novel, blockbuster drugs.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company´s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
For more information:
Contact: Mark de Boer, Ph.D. - CEO
Address: Kapucijnenvoer, 33, 6 floor, 3000 Leuven, Belgium
Tel: 32-16 29 29 23
Fax: 32-16 29 06 92
E-mail: mark.deboer@4aza.com
PDF version press release
http://hugin.info/136226/R/1023605/162169.pdf
The announcement distributed by directnews.
The issuer is solely responsible for the content of this announcement.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release direct/ 4AZA Bioscience N.V. (BE): 4AZA BIOSCIENCE ANNOUNCES RESEARCH COLLABORATION WITH GILEAD here
News-ID: 601 • Views: …
More Releases for AZA
Seasoned Intellectual Property Attorney Alisa Lipski Joins Houston Litigation Bo …
HOUSTON – Accomplished attorney Alisa Lipski brings a decade of patent practice and a science background to the burgeoning intellectual property practice at Houston-based commercial litigation boutique Ahmad, Zavitsanos, Anaipakos, Alavi & Mensing P.C., or AZA.
Ms. Lipski is licensed to practice before the U.S. Patent and Trademark Office and has handled numerous Markman hearings in District Courts around the country as well as several appellate arguments before the U.S.…
Houston Complex Commercial Litigation Firm AZA Hires Two New Associates
HOUSTON – The Houston complex commercial litigation and intellectual property firm Ahmad, Zavitsanos, Anaipakos, Alavi & Mensing P.C. (AZA) is announcing the hiring of two new associates.
Diane Guillerman joins the firm with more than 12 years of experience in litigation and appellate matters, including prior work as a chambers attorney for then-Texas 14th Court of Appeals Justice Eva Guzman.
Reed Smith has clerked for two federal judges, including one on…
Lawyers from Houston Complex Commercial Litigation Boutique AZA
HOUSTON – The Houston complex commercial litigation law firm of Ahmad, Zavitsanos, Anaipakos, Alavi & Mensing P.C. once again is home to four lawyers on the prestigious Texas Super Lawyers listing of the state’s top attorneys.
Joe Ahmad, John Zavitsanos, Demetrios Anaipakos and Amir Alavi all were named among the top lawyers in the state. Mr. Ahmad and Mr. Zavitsanos earned additional honors by being named among the Top 100 Lawyers…
Houston Commercial Litigation Firm AZA Wins Appeal in Continental Pilot Divorce …
HOUSTON – The 5th U.S. Circuit Court of Appeals has sided with a group of Continental Airlines pilots in a dispute with the airline over early pension benefit payouts and the legality of their divorces, lawyers from Houston-based complex commercial litigation firm Ahmad, Zavitsanos & Anaipakos announced Tuesday.
AZA attorneys Joe Ahmad and Steve Mitby, along with Houston attorney Howard Dulmage, represent five of nine Continental pilots who resigned or were…
AZA Welcomes Houston Complex Commercial Litigation Lawyer Tim Shelby
HOUSTON – The complex commercial litigation law firm of Ahmad, Zavitsanos & Anaipakos is proud to announce the addition of accomplished courtroom attorney Tim Shelby.
Mr. Shelby has been recognized repeatedly as one of the top young lawyers in Texas, including multiple appearances in the Texas Rising Stars list based on his expertise in business litigation. His practice focuses on complex commercial litigation as well as energy litigation, securities litigation, professional…
AZA Partners in Houston Commercial Litigation Firm Earn Prestigious Legal Certif …
HOUSTON – The Houston complex commercial litigation law firm of Ahmad, Zavitsanos & Anaipakos is pleased to announce that three more firm partners have been Board Certified in Civil Trial Law by the Texas Board of Legal Specialization.
AZA’s Demetrios Anaipakos, Amir Alavi, and Todd W. Mensing are now among only 1.6 percent of Texas lawyers certified as civil trial law specialists. Nine attorneys were granted that high honor statewide…
